检验后阶段转录错误的范围探索:VIPVIZA研究中的干预
该研究在VIPVIZA研究中检查血脂变量转录错误的规模,并评估研究人员教育是否降低随访时错误频率。转录错误频率在2019年数据库为0.55%,教育干预后2023年减半至0.25%。在39名总胆固醇或HDL胆固醇转录错误者中,6人(15%)因错误被归入不正确的SCORE2风险类别。
要点
- 血脂转录错误频率为0.55%,教育干预后降至0.25%。
- 总胆固醇或HDL胆固醇转录错误者中15%被错误分类SCORE2风险。
- 应尽量减少实验室外领域的转录,以确保基于检验结果的临床决策准确。
核心结论
- 尽管数字化改进,转录错误仍持续存在,且可能影响基于检验结果的临床风险分类。
研究设计与样本
- VIPVIZA研究纳入血脂参数评估,研究护士将总胆固醇、甘油三酯、HDL胆固醇和计算LDL胆固醇结果转录至研究数据库。
- 通过重新计算LDL胆固醇识别转录错误,差异>0.15提示任一血脂参数转录错误。
- 比较基于错误血脂水平与正确血脂水平的个体SCORE2风险类别以评估风险分类错误。
主要发现
- 2019年VIPVIZA研究数据库中转录错误频率为0.55%。
- 教育干预后2023年转录错误频率减半至0.25%。
- 39名总胆固醇或HDL胆固醇转录错误者中,6人(15%)因错误获得不正确的风险类别。
关键数值与推荐
- LDL胆固醇重新计算差异>0.15指示任一血脂参数转录错误。
- 转录错误频率:2019年0.55%,2023年0.25%。
- 总胆固醇或HDL胆固醇转录错误者中15%被错误分类SCORE2风险类别。
临床怎么用
- 应尽量减少实验室外领域的转录,以降低检验后错误对临床决策的影响。
- 基于检验结果的SCORE2风险算法依赖准确信息,需关注非实验室报告环节的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We examined the magnitude of transcription errors in lipid variables in the VIPVIZA study and assessed whether education among the research personnel reduced the error frequency at follow-up. We also examined how the errors affected the SCORE2 risk prediction algorithm for cardiovascular disease, which includes lipid parameters, as this could lead to an incorrect treatment decision. METHODS: The VIPVIZA study includes assessment of lipid parameters, where results for total cholesterol, triglycerides, HDL cholesterol, and calculated LDL cholesterol are transcribed into the research database by research nurses. Transcription errors were identified by recalculating LDL cholesterol, and a difference>0.15 indicated a transcription error in any of the four lipid parameters. To assess the presence of risk category misclassification, we compared the individual's SCORE2 risk category based on incorrect lipid levels to the SCORE2 categories based on the correct lipid levels. RESULTS: The transcription error frequency was 0.55 % in the 2019 VIPVIZA research database and halved after the educational intervention to 0.25 % in 2023. Of the 39 individuals who had a transcription error in total or HDL cholesterol (with the possibility of affecting the SCORE2 risk category based on non-HDL cholesterol), six individuals (15 %) received an incorrect risk category due to the error. CONCLUSIONS: Transcription errors persist despite digitalisation improvements. It is essential to minimise transcriptions in fields outside the laboratory environment, as we observed that critical decisions also rely on accurate information such as the SCORE2-risk algorithm, which is dependent on lab results but not necessarily reported by the laboratory.
引用
- Mickelsson M, Ekblom K, Stefansson K, et al. Exploring the extent of post-analytical errors, with a focus on transcription errors - an intervention within the VIPVIZA study. Clin Chem Lab Med. 2025. PMID: 40021473. doi:10.1515/cclm-2025-0009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。